<DOC>
	<DOCNO>NCT02754141</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacodynamics , anti-tumor activity , pharmacokinetics BMS-986179 combine nivolumab patient advance cancer .</brief_summary>
	<brief_title>A Study BMS-986179 Administered Combination With Nivolumab Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Men woman least 18 year age Advanced solid tumor Eastern Cooperative Oncology Group ( ECOG ) 01 Acceptable lab test result Allow biopsies Central nervous system ( CNS ) tumor Uncontrolled significant cardiovascular disease Active know autoimmune disease Organ transplant Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>